OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma

NCT00193154 ↗

Phase 2 Completed 63 enrolled SCRI Development Innovations, LLC AstraZeneca · collab Genentech, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

In this phase II trial, we plan to evaluate the combination of Tarceva and Avastin in the treatment of patients with metastatic renal cell carcinoma. This trial will be one of the first phase II trials to evaluate a combination of targeted agents in the treatment of a common solid tumor with a strong biologic rationale based on Cancer Biology (VHL/HIF/VEGF/EGFr).

Timeline

Start: 2003-02
Primary completion: 2004-01
Completion: 2014-03

Publications

Results Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol. 2005 Nov 1;23(31):7889-96. doi: 10.1200/JCO.2005.01.8234. Epub 2005 Oct 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Erlotinib	Small molecule	150 mg	Oral

OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma

Summary

Timeline

Publications

Drugs

Indications